News | Published: Monday, October 16, 2023 9:00 am
HeartX, powered by HealthTech Arkansas and MedAxiom along with eleven leading cardiology practices in Arkansas and around the country — has selected the startup healthcare companies that will participate in the 2023 accelerator program. HeartX is a cardiovascular-focused healthcare accelerator that facilitates guaranteed hospital pilot projects and clinical trials for accomplished, early-stage companies bringing new cardiovascular innovations to market. More information about HeartX can be found at HeartXAccelerator.com.
The companies selected for the 2023 HeartX program pitched to both MedAxiom Innovation Xchange participants and general attendees at CV Transforum Fall’23. Conference attendees were able to see samples and ask questions about the science behind the device technology. Joe Sasson, PhD, MedAxiom’s chief commercial officer and executive vice president of Ventures, emphasized that participation in HeartX will allow companies to make their technologies more sustainable in the market. HeartX is designed to help cohort participants understand a specific technology’s potential in the context of both the cardiovascular service line and the subset of patients affected.
The 2023 HeartX companies are:
Happitech, Netherlands
Happitech offers an accessible and scalable solution for identifying patients at risk of atrial fibrillation (AF). By placing a finger on a smartphone's camera for 90 seconds, individuals can screen for AF with a sensitivity and specificity similar to the standard of care. This is well suited for at-risk underserved populations, the elderly, and low-income individuals promoting improved health equity. Learn more at happitech.com.
MindMics, Massachusetts, United States
MindMics delivers heart monitoring through low-frequency acoustical vibrations detected in the ear canal with technology embedded in earbuds and hearing aids. The results are highly accurate regardless of skin tone, skin thickness, and body mass. The sound-based technology has been clinically validated in collaboration with leading researchers and world-renowned medical institutions. Learn more at mindmics.com.
Nanowear, New York, United States
Nanowear is an AI-based remote diagnostics tool utilizing proprietary patented cloth-based nanotechnology. The nanosensors capture over 85 medical-grade biomarkers directly from the skin, enabling a closed-loop digital system for specific machine-learning algorithms built on terabytes of unique human data. Learn more at nanowearinc.com.
SmartCardia, Switzerland
SmartCardia produces the 7L Patch, a revolutionary platform and 7-Lead ECG patch for cardiology and remote patient monitoring (RPM) that is a breakthrough 7/14 day patch offering real-time 7-Lead ECG and vitals with SaaS. A single patch serves multiple service types: Mobile Cardiac Telemetry, RPM, Holter, Extended Holter, and Event Monitoring. Learn more at smartcardia.com.
“We are excited to reveal the 2023 HeartX cohort companies, which were hand-selected by our participating cardiology practices,” said Jeff Stinson, director of HealthTech Arkansas. “With MedAxiom’s help, we’ve been able to grow the HeartX program to international prominence. Through the guaranteed clinical engagement and the national visibility provided through MedAxiom’s national network of cardiology practices, we’re now attracting the very best cardiovascular startups from around the world. We’re very grateful for this opportunity.”
“The cardiovascular industry has been at the forefront of healthcare innovation and new technologies and solutions are arising at a rapid pace. We’re excited to partner with five companies that are transforming cardiovascular care around the world as part of the 2023 HeartX program. While the heart of the program remains in Arkansas, we’ve expanded clinical trial sites nationwide to advance innovations that promise to improve care delivery. With two cohorts now a part of HeartX, MedAxiom and HealthTech Arkansas are committed to expanding the portfolio to provide revolutionary solutions to patients, providers and programs,” said Sasson.
Representatives from each of the eleven cardiology practices, plus representatives from HealthTech Arkansas and MedAxiom, interviewed applicants and selected companies with technologies that have the potential to advance cardiovascular innovation and cardiac care at their respective organizations. Each company will receive $150,000 of investment capital as well as complete and total access to clinicians and administrators while executing their pilot projects and clinical studies in the HeartX program. Participants will also receive guidance on defining the scope of their clinical studies from a clinical trials manager.
By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.
